Evidence for Human Diabetic Cardiomyopathy
Overview
Affiliations
Growing interest has been accumulated in the definition of worsening effects of diabetes in the cardiovascular system. This is associated with epidemiological data regarding the high incidence of heart failure (HF) in diabetic patients. To investigate the detrimental effects both of hyperglycemia and insulin resistance, a lot of preclinical models were developed. However, the evidence of pathogenic and histological alterations of the so-called diabetic cardiomyopathy (DCM) is still poorly understood in humans. Here, we provide a stringent literature analysis to investigate unique data regarding human DCM. This approach established that lipotoxic-related events might play a central role in the initiation and progression of human DCM. The major limitation in the acquisition of human data is due to the fact of heart specimen availability. Postmortem analysis revealed the end stage of the disease; thus, we need to gain knowledge on the pathogenic events from the early stages until cardiac fibrosis underlying the end-stage HF.
Role of Circulating Biomarkers in Diabetic Cardiomyopathy.
Ianos R, Cozma A, Lucaciu R, Hangan A, Negrean V, Mercea D Biomedicines. 2024; 12(9).
PMID: 39335666 PMC: 11428922. DOI: 10.3390/biomedicines12092153.
Moka M, K S, George M Acta Diabetol. 2024; 62(1):1-10.
PMID: 39254745 DOI: 10.1007/s00592-024-02363-5.
Song K, Liang D, Xiao D, Kang A, Ren Y Mol Med Rep. 2024; 30(5).
PMID: 39239741 PMC: 11411234. DOI: 10.3892/mmr.2024.13323.
A Review on the Natural Products in Treatment of Diabetic Cardiomyopathy (DCM).
Yao P, Yang X, Qiao Y Rev Cardiovasc Med. 2024; 25(5):165.
PMID: 39076497 PMC: 11267204. DOI: 10.31083/j.rcm2505165.
Diabetic Cardiomyopathy-From Basics through Diagnosis to Treatment.
Radzioch E, Dabek B, Balcerczyk-Lis M, Frak W, Fularski P, Mlynarska E Biomedicines. 2024; 12(4).
PMID: 38672121 PMC: 11048005. DOI: 10.3390/biomedicines12040765.